Adverse Event reporting information can be found in footer
Request a Meeting
Urinary-associated problems, e.g. obstructive uropathy leading to persistent infections and LUTS
As a result of arthralgia, or eventually bone metastases which can lead to fractures and spinal cord compression
† Absolute values for joint-related signs and symptoms are not reported in the paper.
‡ Crude incidence of a urinary tract event was 12% vs. 18% for FIRMAGON® and LHRH agonist respectively.
§ Crude incidence of a musculoskeletal event was 8% vs. 12% for FIRMAGON® and LHRH agonist respectively
Compared with LHRH agonists, FIRMAGON® blocks GnRH receptors leading to a rapid, profound and sustained suppression of testosterone, FSH, LH and PSA5
Use the buttons below to choose
A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing a musculoskeletal event1
A pooled analysis of 5 randomised controlled trials by Klotz et al. 2014 revealed the probability of experiencing renal or LUTS adverse event1
References
1. Klotz L, et al. Eur Urol 2014;66:1101–1108.
2. NHS. Prostate cancer. Symptoms. Available at: https://www.nhs.uk/conditions/prostate-cancer/symptoms/. Last accessed: February 2024.
3. Prostate Cancer UK. Living with prostate cancer. Available at: https://prostatecanceruk.org/prostate-information/living-with-prostate-cancer. Last accessed: February 2024.
4. Drudge-Coates L. Int J Urol Nurs 2009;3(3):85–92.
5. Klotz L, et al. BJU Int 2008;102:1531-1538.
Job Code: UK-FN-2400005 - Date of Preparation: March 2024